Lunai Bioworks
LNAILNAI · Stock Price
Historical price data
Overview
Lunai Bioworks is a public biotech company (LNAI) on a mission to decode disease biology by creating a continuous, integrated system where AI-driven insights are rapidly validated in living models. Founded in 2021, the company has developed a validated platform combining its Augusta AI engine, Phenograph translational system, and high-throughput zebrafish models to identify novel therapeutic targets and biomarkers. Its strategy focuses on advancing internal programs and strategic partnerships in complex therapeutic areas like oncology and neurology, aiming to compress drug discovery timelines and reduce clinical attrition.
Technology Platform
An integrated, closed-loop platform combining the Augusta AI/ML engine for multi-omic analysis, the Phenograph system for therapeutic strategy translation, and high-throughput in vivo zebrafish models with machine vision for biological validation.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Lunai competes with integrated AI-biotechs (e.g., Recursion, Exscientia), AI software providers (e.g., Schrödinger, Relay Therapeutics), and traditional CROs adding AI capabilities. Its key differentiator is the proprietary, closed-loop integration of its AI engine with high-throughput in vivo zebrafish validation, aiming for greater physiological relevance at scale compared to purely in silico or in vitro competitors.
